GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innoviva Inc (NAS:INVA) » Definitions » Cyclically Adjusted Price-to-FCF

Innoviva (Innoviva) Cyclically Adjusted Price-to-FCF : 8.47 (As of Jun. 05, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Innoviva Cyclically Adjusted Price-to-FCF?

As of today (2024-06-05), Innoviva's current share price is $16.015. Innoviva's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was $1.89. Innoviva's Cyclically Adjusted Price-to-FCF for today is 8.47.

The historical rank and industry rank for Innoviva's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

INVA' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 7.2   Med: 14.94   Max: 361.5
Current: 8.45

During the past years, Innoviva's highest Cyclically Adjusted Price-to-FCF was 361.50. The lowest was 7.20. And the median was 14.94.

INVA's Cyclically Adjusted Price-to-FCF is ranked better than
96.23% of 106 companies
in the Biotechnology industry
Industry Median: 49.55 vs INVA: 8.45

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Innoviva's adjusted free cash flow per share data for the three months ended in Mar. 2024 was $0.438. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $1.89 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Innoviva Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Innoviva's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innoviva Cyclically Adjusted Price-to-FCF Chart

Innoviva Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 37.55 19.23 9.79 9.17

Innoviva Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.77 8.03 7.58 9.17 8.08

Competitive Comparison of Innoviva's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Innoviva's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innoviva's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innoviva's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Innoviva's Cyclically Adjusted Price-to-FCF falls into.



Innoviva Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Innoviva's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=16.015/1.89
=8.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innoviva's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Innoviva's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.438/131.7762*131.7762
=0.438

Current CPI (Mar. 2024) = 131.7762.

Innoviva Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -1.382 100.560 -1.811
201409 0.698 100.428 0.916
201412 -0.041 99.070 -0.055
201503 -0.014 99.621 -0.019
201506 0.019 100.684 0.025
201509 0.023 100.392 0.030
201512 0.060 99.792 0.079
201603 0.064 100.470 0.084
201606 0.100 101.688 0.130
201609 0.165 101.861 0.213
201612 0.133 101.863 0.172
201703 0.231 102.862 0.296
201706 0.188 103.349 0.240
201709 0.363 104.136 0.459
201712 0.402 104.011 0.509
201803 0.440 105.290 0.551
201806 0.456 106.317 0.565
201809 0.530 106.507 0.656
201812 0.545 105.998 0.678
201903 0.676 107.251 0.831
201906 0.498 108.070 0.607
201909 0.506 108.329 0.616
201912 0.590 108.420 0.717
202003 0.647 108.902 0.783
202006 0.703 108.767 0.852
202009 0.656 109.815 0.787
202012 0.751 109.897 0.901
202103 0.740 111.754 0.873
202106 0.841 114.631 0.967
202109 1.184 115.734 1.348
202112 1.205 117.630 1.350
202203 1.047 121.301 1.137
202206 0.826 125.017 0.871
202209 0.164 125.227 0.173
202212 0.093 125.222 0.098
202303 0.286 127.348 0.296
202306 0.583 128.729 0.597
202309 0.507 129.860 0.514
202312 0.390 129.419 0.397
202403 0.438 131.776 0.438

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Innoviva  (NAS:INVA) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Innoviva Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Innoviva's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Innoviva (Innoviva) Business Description

Industry
Traded in Other Exchanges
Address
1350 Old Bayshore Highway, Suite 400, Burlingame, CA, USA, 94010
Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline.
Executives
Marianne Zhen officer: Chief Accounting Officer C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005
Stephen Basso officer: Chief Financial Officer C/O INOZYME PHARMA, INC., 321 SUMMER STREET, SUITE 400, BOSTON MA 02210
Margaret Koziel officer: Chief Medical Officer C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Alexander J Denner 10 percent owner C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Deborah Birx director 3300 LOWELL STREET NW, WASHINGTON DC 20008
Sarissa Capital Management Lp 10 percent owner 660 STEAMBOAT ROAD, GREENWICH CT 06830
Pavel Raifeld officer: Chief Executive Officer 1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME CA 94010
Sapna Srivastava director C/O MYOS CORPORATION, 45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS NJ 07927
Larry G. Edwards officer: CEO of La Jolla Pharmaceutical C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Plc Glaxosmithkline 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Mark Dipaolo director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Kostas D Odysseas director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarah J. Schlesinger director C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jules Haimovitz director 601 108TH AVENUE NE, SUITE 1200, BELLEVUE WA 98004
George Bickerstaff director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511